Clinical Research Directory

Inclusion Criteria: * Patients with a confirmed Dravet syndrome or Lennox-Gastaut syndrome diagnosis who are eligible for Fenfluramine. * Patients for which the neurologist decided to prescribe Fenfluramine as a relevant treatment approach and who have not been prescribed Fenfluramine before. * Patients or caregivers should be able and willing to maintain a seizure diary e.g. using a digital seizure diary. Exclusion Criteria: Patients who * Have been diagnosed with or are suspected to have life-threatening conditions that could result in immediate danger; * Need to undergo an MRI scan or cardiac defibrillation; * Have an active implanted device such as a pacemaker, defibrillator, or vagal nerve, or brain stimulator; * Are unable to provide written informed consent, either directly or via a legal guardian. * Have known allergy or skin-sensitivity to the materials used in the Byteflies Adhesives * Are between 0 and 3 years of age; * Are above weight allowing variable titration * The patient is on any medication that would be contra-indicated for use with Fenfluramine at the execution of the study eg. LP352 (bexicaserin), loracaserin, monoamine-oxidase inhibitors, SSRIs, SNRIs, tricyclic antidepressants or other serotonergic agonists or antagonists (antipsychotics). * Have a prescribed concomitant use of Stiripentol * Have any other condition or finding that would compromise the safety of the participant or the quality of the data, or otherwise interfere with achieving the objectives. * A history of cardiovascular or cerebrovascular disease, aortic or mitral valve regurgitation diagnosed by echography * Patients/caregivers who have only reported/detected non-motor seizures